PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23752175-0	2013	Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.	KPT-276	135-142	exportin 1	Homo sapiens	49-53	
23752175-0	2013	Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.	KPT-276	135-142	exportin 1	Homo sapiens	54-58	
23752175-6	2013	A selective inhibitor of nuclear export compound KPT-276 specifically and irreversibly inhibits the nuclear export function of XPO1.	KPT-276	49-56	exportin 1	Homo sapiens	127-131	
23752175-10	2013	Western blotting and reverse transcription-PCR confirm that c-MYC, CDC25A and BRD4 are all downregulated after treatment with KPT-276.	KPT-276	126-133	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	60-65	
23752175-10	2013	Western blotting and reverse transcription-PCR confirm that c-MYC, CDC25A and BRD4 are all downregulated after treatment with KPT-276.	KPT-276	126-133	cell division cycle 25A	Homo sapiens	67-73	
23752175-10	2013	Western blotting and reverse transcription-PCR confirm that c-MYC, CDC25A and BRD4 are all downregulated after treatment with KPT-276.	KPT-276	126-133	bromodomain containing 4	Homo sapiens	78-82